{"id":"ntrk","name":"NTRK","symbol":"NTRK1/2/3","route":"/targets/ntrk/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8031","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198400","uniprot":"https://www.uniprot.org/uniprotkb/P04629/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P04629","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2815","open-targets":"https://platform.opentargets.org/target/ENSG00000198400","civic":"https://civicdb.org/genes/4914/summary","oncokb":"https://www.oncokb.org/gene/NTRK1","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NTRK1","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=NTRK1","depmap":"https://depmap.org/portal/gene/NTRK1?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000198400-NTRK1","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/4914","omim":"https://www.omim.org/entry/191315"},{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8032","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000148053","uniprot":"https://www.uniprot.org/uniprotkb/Q16620/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q16620","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL4898","open-targets":"https://platform.opentargets.org/target/ENSG00000148053","civic":"https://civicdb.org/genes/4915/summary","oncokb":"https://www.oncokb.org/gene/NTRK2","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NTRK2","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=NTRK2","depmap":"https://depmap.org/portal/gene/NTRK2?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000148053-NTRK2","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/4915","omim":"https://www.omim.org/entry/600456"},{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8033","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000140538","uniprot":"https://www.uniprot.org/uniprotkb/Q16288/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q16288","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL5608","open-targets":"https://platform.opentargets.org/target/ENSG00000140538","civic":"https://civicdb.org/genes/4916/summary","oncokb":"https://www.oncokb.org/gene/NTRK3","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NTRK3","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=NTRK3","depmap":"https://depmap.org/portal/gene/NTRK3?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000140538-NTRK3","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/4916","omim":"https://www.omim.org/entry/191316"}],"products":[{"id":"entrectinib","name":"Entrectinib","status":"approved","modality":"Small-molecule TRK/ROS1/ALK TKI (CNS-penetrant)","route":"/drugs/entrectinib/"},{"id":"larotrectinib","name":"Larotrectinib","status":"approved","modality":"Small-molecule pan-TRK inhibitor (first generation)","route":"/drugs/larotrectinib/"},{"id":"repotrectinib","name":"Repotrectinib","status":"approved","modality":"Small-molecule kinase inhibitor (ROS1 / NTRK)","route":"/drugs/repotrectinib/"},{"id":"trk-950","name":"TRK-950","status":"phase-2","modality":"monoclonal antibody (per the sponsor's pipeline page; form not stated in the registry record)","route":"/drugs/trk-950/"},{"id":"trusight-oncology-comprehensive","name":"TruSight Oncology Comprehensive","status":"approved","modality":"Distributable tissue NGS companion diagnostic test (500+ genes, DNA and RNA)","route":"/drugs/trusight-oncology-comprehensive/"}],"trials":[{"id":"nct05170204","name":"A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small C","nct":"NCT05170204","phase":"3","status":"active"},{"id":"nct06140836","name":"A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)","nct":"NCT06140836","phase":"3","status":"active"},{"id":"nct04603807","name":"A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases","nct":"NCT04603807","phase":"3","status":"active"},{"id":"pediatric-match","name":"NCI-COG Pediatric MATCH (APEC1621)","nct":"NCT03155620","phase":"platform","status":"active"},{"id":"nci-match","name":"NCI-MATCH (EAY131)","nct":"NCT02465060","phase":"platform","status":"active"},{"id":"determine-trial","name":"DETERMINE","nct":"NCT05722886","phase":"platform","status":"recruiting"},{"id":"cupisco","name":"CUPISCO","nct":"NCT03498521","phase":"2","status":"positive"},{"id":"navigate","name":"NAVIGATE","nct":"NCT02576431","phase":"2","status":"positive"},{"id":"nct04302025","name":"A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)","nct":"NCT04302025","phase":"2","status":"recruiting"},{"id":"nct06038578","name":"A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer","nct":"NCT06038578","phase":"2","status":"recruiting"},{"id":"nct06010342","name":"A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients","nct":"NCT06010342","phase":"2","status":"recruiting"},{"id":"nct02568267","name":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangeme","nct":"NCT02568267","phase":"2","status":"active"},{"id":"nct06315010","name":"Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis","nct":"NCT06315010","phase":"2","status":"recruiting"},{"id":"nct05725200","name":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer","nct":"NCT05725200","phase":"2","status":"recruiting"},{"id":"nct04589845","name":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","nct":"NCT04589845","phase":"2","status":"active"},{"id":"nct03093116","name":"A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements","nct":"NCT03093116","phase":"1/2","status":"recruiting"},{"id":"nct04094610","name":"A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations","nct":"NCT04094610","phase":"1/2","status":"recruiting"},{"id":"nct05423262","name":"A Study of TRK-950 in Patients With Advanced Solid Tumors","nct":"NCT05423262","phase":"1/2","status":"recruiting"},{"id":"nct02637687","name":"A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children","nct":"NCT02637687","phase":"1/2","status":"active"},{"id":"nct02650401","name":"Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options","nct":"NCT02650401","phase":"1/2","status":"active"},{"id":"profile-1001-ros1","name":"PROFILE 1001 ROS1 expansion cohort","nct":"NCT00585195","phase":"1","status":"positive"}],"pathways":["thyroid-cancer-signalling"],"companies":["bayer","bms","illumina","lucence","roche-genentech","toray-industries"],"keyPapers":["paper-giraldo-gallbladder-msk-impact-ccr-2022","paper-philip-kras-wild-type-pancreatic-ccr-2022","paper-oreilly-hechtman-ntrk-fusion-pancreatic-larotrectinib-ann-oncol-2019"],"hotspots":[{"label":"G595R (solvent front)","position":595,"kind":"resistance","drugs":["repotrectinib"]},{"label":"G667C (xDFG) and F589L (gatekeeper)","position":667,"kind":"resistance","drugs":["repotrectinib"]}],"openQuestions":[],"assays":[{"id":"foundationone-cdx-panel","name":"FoundationOne CDx","cutoff":"Per companion claim: EGFR, ALK, BRAF V600, ERBB2 amplification, KRAS wild-type, BRCA1/2 and HRR genes, PIK3CA, MET exon 14, RET, FGFR2 fusions, IDH1, NTRK fusions; MSI-high; TMB at least 10 mutations per megabase"},{"id":"foundationone-liquid-cdx","name":"FoundationOne Liquid CDx","cutoff":"Per companion claim: EGFR (osimertinib, erlotinib, gefitinib), ALK (alectinib), BRCA1/2 and ATM (olaparib, rucaparib), PIK3CA (alpelisib), FGFR3 (erdafitinib), NTRK and RET; negative plasma results reflex to tissue"}],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}